Pharmacokinetics, Pharmacodynamics and Safety of Belimumab in Chinese Patients with Systemic Lupus Erythematosus: A Phase I, Open-Label Study

ConclusionPK of a single belimumab 10 mg/kg IV dose in Chinese patients with SLE were similar to those observed previously in Japanese and American (white and African-American) patients with SLE. PD results were consistent with belimumab inhibiting BLyS, and belimumab was well tolerated. These data support the use of belimumab in Chin ese patients with SLE.Trial RegistrationClinicalTrials.gov identifier, NCT02880852.

http://link.springer.com/10.1007/s40744-020-00193-9

Source: Rheumatology and Therapy - January 16, 2020 Category: Rheumatology Source Type: research